{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-066698","form_type":"8-K","ticker":"AMST","cik":"0001807166","company_name":"Amesite Inc.","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.230504+00:00","generated_at":"2026-06-27T23:24:32.690702+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Amesite terminates CFO Matthew Kern, appoints Mark Corrao as CFO effective Dec 15, 2021","bullets":["Matthew Kern terminated as CFO on Dec 15, 2021; Mark Corrao appointed same day.","Corrao serves as non-employee, part-time CFO; compensation $3,000 signing + $3,000/month.","Corrao is also CFO of Neuropathix and former CFO of Generex Biotechnology and Brain Scientific.","Agreement includes indemnification and D&O insurance; term is one year, extendable by mutual consent.","Corrao remains independent CFO; company also retains The CFO Squad LLC for pre-audit and SEC compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-066698","json":"https://secwatch.observer/filing/0001213900-21-066698.json","markdown":"https://secwatch.observer/filing/0001213900-21-066698.md","text":"https://secwatch.observer/filing/0001213900-21-066698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/0001213900-21-066698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/ea152831-8k_amesite.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:24:32.690702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29c4d947d4","claim":"Matthew Kern was terminated as Chief Financial Officer at Amesite Inc..","evidence_excerpt":"On December 15, 2021 (the “Effective Date”), the board of directors (the “Board”) of Amesite Inc. (the “Company”) authorized and approved the termination of Matthew Kern as Chief Financial Officer of the Company, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/0001213900-21-066698-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"4c89628fe6","claim":"Mark Corrao was appointed as Chief Financial Officer at Amesite Inc..","evidence_excerpt":"In addition, on December 15, 2021, in connection with the termination of Mr. Kern, the Board authorized and approved the appointment of Mark Corrao, age 64, as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807166/000121390021066698/0001213900-21-066698-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}